Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer

Casey W. Williamson; Nikhil V. Kotha; Jingjing Zou; Derek Brown; Daniel Scanderbeg; Dominique Rash; John Einck; Catheryn Yashar; Loren K. Mell; Jyoti Mayadev

doi:10.1016/j.brachy.2022.12.005

Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer

Casey W. Williamson, Nikhil V. Kotha, Jingjing Zou, Derek Brown, Daniel Scanderbeg, Dominique Rash, John Einck, Catheryn Yashar, Loren K. Mell, Jyoti Mayadev

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

PURPOSE: To estimate local control, survival, and toxicity associated with a 3-fraction (3F) image-guided brachytherapy (IGBT) regimen compared to longer fraction (LF) for cervical cancer. METHODS: 150 patients treated between 2015-2020 with 3F (24Gy in 3 fractions) or LF (28…30 Gy in 4-5 fractions) were reviewed. The primary outcome was 2-year local failure. We compared overall survival (OS), disease-free survival (DFS), hospitalizations, and toxicity. RESULTS: There were 32 patients in the 3F group and 118 in the LF group, with a median follow up of 22 months. The 3F had worse performance status (p = 0.01) but otherwise similar characteristics. The 2-year local failure rate was 3.6% (95% CI 0%, 10.6%) for 3F, and 7.5% (95% CI 2.4%, 12.6%) for LF. The univariable hazard ratio (HR) for local failure for 3F was 0.43 (0.05, 3.43; p = 0.43). Moreover, 2 of 32 (6.3%) 3F patients experienced Grade …3 toxicity compared to 7 of 118 (5.9%) LF patients (p = 1.0), with no difference in hospitalization within 2 years (p = 0.66) and no treatment-related deaths. CONCLUSIONS: Local control was excellent, with long term survival and toxicity similar between the groups. These findings support consideration of 3F.

Original language	English (US)
Pages (from-to)	317-324
Number of pages	8
Journal	Brachytherapy
Volume	22
Issue number	3
DOIs	https://doi.org/10.1016/j.brachy.2022.12.005
State	Published - May 1 2023

Keywords

Cervical cancer
HDR brachytherapy
Hypofractionation

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.brachy.2022.12.005

Cite this

@article{b3ea777ee9ea4716b4903eeaa8912619,

title = "Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer",

abstract = "PURPOSE: To estimate local control, survival, and toxicity associated with a 3-fraction (3F) image-guided brachytherapy (IGBT) regimen compared to longer fraction (LF) for cervical cancer. METHODS: 150 patients treated between 2015-2020 with 3F (24Gy in 3 fractions) or LF (28…30 Gy in 4-5 fractions) were reviewed. The primary outcome was 2-year local failure. We compared overall survival (OS), disease-free survival (DFS), hospitalizations, and toxicity. RESULTS: There were 32 patients in the 3F group and 118 in the LF group, with a median follow up of 22 months. The 3F had worse performance status (p = 0.01) but otherwise similar characteristics. The 2-year local failure rate was 3.6% (95% CI 0%, 10.6%) for 3F, and 7.5% (95% CI 2.4%, 12.6%) for LF. The univariable hazard ratio (HR) for local failure for 3F was 0.43 (0.05, 3.43; p = 0.43). Moreover, 2 of 32 (6.3%) 3F patients experienced Grade …3 toxicity compared to 7 of 118 (5.9%) LF patients (p = 1.0), with no difference in hospitalization within 2 years (p = 0.66) and no treatment-related deaths. CONCLUSIONS: Local control was excellent, with long term survival and toxicity similar between the groups. These findings support consideration of 3F.",

keywords = "Cervical cancer, HDR brachytherapy, Hypofractionation",

author = "Williamson, {Casey W.} and Kotha, {Nikhil V.} and Jingjing Zou and Derek Brown and Daniel Scanderbeg and Dominique Rash and John Einck and Catheryn Yashar and Mell, {Loren K.} and Jyoti Mayadev",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = may,

day = "1",

doi = "10.1016/j.brachy.2022.12.005",

language = "English (US)",

volume = "22",

pages = "317--324",

journal = "Brachytherapy",

issn = "1538-4721",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer

AU - Williamson, Casey W.

AU - Kotha, Nikhil V.

AU - Zou, Jingjing

AU - Brown, Derek

AU - Scanderbeg, Daniel

AU - Rash, Dominique

AU - Einck, John

AU - Yashar, Catheryn

AU - Mell, Loren K.

AU - Mayadev, Jyoti

PY - 2023/5/1

Y1 - 2023/5/1

N2 - PURPOSE: To estimate local control, survival, and toxicity associated with a 3-fraction (3F) image-guided brachytherapy (IGBT) regimen compared to longer fraction (LF) for cervical cancer. METHODS: 150 patients treated between 2015-2020 with 3F (24Gy in 3 fractions) or LF (28…30 Gy in 4-5 fractions) were reviewed. The primary outcome was 2-year local failure. We compared overall survival (OS), disease-free survival (DFS), hospitalizations, and toxicity. RESULTS: There were 32 patients in the 3F group and 118 in the LF group, with a median follow up of 22 months. The 3F had worse performance status (p = 0.01) but otherwise similar characteristics. The 2-year local failure rate was 3.6% (95% CI 0%, 10.6%) for 3F, and 7.5% (95% CI 2.4%, 12.6%) for LF. The univariable hazard ratio (HR) for local failure for 3F was 0.43 (0.05, 3.43; p = 0.43). Moreover, 2 of 32 (6.3%) 3F patients experienced Grade …3 toxicity compared to 7 of 118 (5.9%) LF patients (p = 1.0), with no difference in hospitalization within 2 years (p = 0.66) and no treatment-related deaths. CONCLUSIONS: Local control was excellent, with long term survival and toxicity similar between the groups. These findings support consideration of 3F.

AB - PURPOSE: To estimate local control, survival, and toxicity associated with a 3-fraction (3F) image-guided brachytherapy (IGBT) regimen compared to longer fraction (LF) for cervical cancer. METHODS: 150 patients treated between 2015-2020 with 3F (24Gy in 3 fractions) or LF (28…30 Gy in 4-5 fractions) were reviewed. The primary outcome was 2-year local failure. We compared overall survival (OS), disease-free survival (DFS), hospitalizations, and toxicity. RESULTS: There were 32 patients in the 3F group and 118 in the LF group, with a median follow up of 22 months. The 3F had worse performance status (p = 0.01) but otherwise similar characteristics. The 2-year local failure rate was 3.6% (95% CI 0%, 10.6%) for 3F, and 7.5% (95% CI 2.4%, 12.6%) for LF. The univariable hazard ratio (HR) for local failure for 3F was 0.43 (0.05, 3.43; p = 0.43). Moreover, 2 of 32 (6.3%) 3F patients experienced Grade …3 toxicity compared to 7 of 118 (5.9%) LF patients (p = 1.0), with no difference in hospitalization within 2 years (p = 0.66) and no treatment-related deaths. CONCLUSIONS: Local control was excellent, with long term survival and toxicity similar between the groups. These findings support consideration of 3F.

KW - Cervical cancer

KW - HDR brachytherapy

KW - Hypofractionation

UR - http://www.scopus.com/inward/record.url?scp=85147025734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147025734&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2022.12.005

DO - 10.1016/j.brachy.2022.12.005

M3 - Article

C2 - 36631374

AN - SCOPUS:85147025734

SN - 1538-4721

VL - 22

SP - 317

EP - 324

JO - Brachytherapy

JF - Brachytherapy

IS - 3

ER -

Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this